In adults with type 2 diabetes mellitus and established/high risk of ASCVD, treatment regimen should include agents that reduce cardiorenal risk, such as an SGLT2 inhibitor or a GLP-1 receptor agonist
Connecting the Dots: GLP-1s Mimic Diabetic Neuropathy This mechanism is identical to the one that causes diabetic neuropathy
Clinical Endocrinology, 98(5), 785-794
Sleep disturbances Some people report insomnia on semaglutide , particularly at higher doses
Chicken: Similar to the chicken, this also contains moderate quantities of L-Carnitine
Retatrutide is a sophisticated polypeptide, a triple agonist targeting the GIP, GLP-1, and glucagon receptors